Effects of aging on glutamate neurotransmission in the substantia nigra of Gdnf heterozygous mice

Neurobiology of Aging

Volumn 36, Issue 3, 2015, Pages 1569-1576

  Farrand, Ariana Q ^a   Gregory, Rebecca A ^a   Scofield, Michael D ^a   Helke, Kristi L ^a   Boger, Heather A ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Glial cell line derived neurotrophic factor (GDNF); Glutamate; Invivo electrochemistry; Neurodegeneration; Striatum; Substantia nigra

Indexed keywords

GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUTAMIC ACID; VESICULAR GLUTAMATE TRANSPORTER 1; VESICULAR GLUTAMATE TRANSPORTER 2; EXCITATORY AMINO ACID TRANSPORTER 2;

AGING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE ASSOCIATION; DOPAMINERGIC NERVE CELL; ELECTROCHEMISTRY; EXCITOTOXICITY; GDNF GENE; GENE; IN VIVO STUDY; MALE; MOUSE; NERVE DEGENERATION; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUBSTANTIA NIGRA; ANIMAL; C57BL MOUSE; DEFICIENCY; FEMALE; GENETICS; HETEROZYGOTE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SECRETION (PROCESS); SUBTHALAMIC NUCLEUS; SYNAPTIC TRANSMISSION;

AGING; ANIMALS; DOPAMINERGIC NEURONS; EXCITATORY AMINO ACID TRANSPORTER 2; FEMALE; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; GLUTAMIC ACID; HETEROZYGOTE; MALE; MICE, INBRED C57BL; NERVE DEGENERATION; SUBSTANTIA NIGRA; SUBTHALAMIC NUCLEUS; SYNAPTIC TRANSMISSION;

EID: 84923597320     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2014.11.017     Document Type: Article

References (43)

1. Blandini F., Porter R.H., Greenamyre J.T. Glutamate and Parkinson's disease. Mol. Neurobiol. 1996, 12:73-94.
2. Boger H.A., Middaugh L.D., Huang P., Zaman V., Smith A.C., Hoffer B.J., Tomac A.C., Granholm A.C. Apartial GDNF depletion leads to earlier age-related deterioration of motor function and tyrosine hydroxylase expression in the substantia nigra. Exp. Neurol. 2006, 202:336-347.
3. Boger H.A., Middaugh L.D., Patrick K.S., Ramamoorthy S., Denehy E.D., Zhu H., Pacchioni A.M., Granholm A.C., McGinty J.F. Long-term consequences of methamphetamine exposure in young adults are exacerbated in glial cell line-derived neurotrophic factor heterozygous mice. J.Neurosci. 2007, 27:8816-8825.
4. Borlongan C.V., Zhou F.C., Hayashi T., Su T.P., Hoffer B.J., Wang Y. Involvement of GDNF in neuronal protection against 6-OHDA-induced parkinsonism following intracerebral transplantation of fetal kidney tissues in adult rats. Neurobiol. Dis. 2001, 8:636-646.
5. Burmeister J.J., Gerhardt G.A. Self-referencing ceramic-based multisite microelectrodes for the detection and elimination of interferences from the measurement of L-glutamate and other analytes. Anal Chem. 2001, 73:1037-1042.
6. Burmeister J.J., Pomerleau F., Palmer M., Day B.K., Huettl P., Gerhardt G.A. Improved ceramic-based multisite microelectrode for rapid measurements of L-glutamate in the CNS. J.Neurosci. Methods 2002, 119:163-171.
7. Chauhan N.B., Siegel G.J., Lee J.M. Depletion of glial cell line-derived neurotrophic factor in substantia nigra neurons of Parkinson's disease brain. J.Chem. Neuroanat. 2001, 21:277-288.
8. Deister C., Schmidt C.E. Optimizing neurotrophic factor combinations for neurite outgrowth. J.Neural Eng. 2006, 3:172-179.
9. Di Liberto V., Mudò G., Belluardo N. mGluR2/3 agonist LY379268, by enhancing the production of GDNF, induces a time-related phosphorylation of RET receptor and intracellular signaling Erk1/2 in mouse striatum. Neuropharmacology 2011, 61:638-645.
10. Favier M., Carcenac C., Drui G., Boulet S., El Mestikawy S., Savasta M. High-frequency stimulation of the subthalamic nucleus modifies the expression of vesicular glutamate transporters in basal ganglia in a rat model of Parkinson's disease. BMC Neurosci. 2013, 14:152.
11. Fieblinger T., Sebastianutto I., Alcacer C., Bimpisidis Z., Maslava N., Sandberg S., Engblom D., Cenci M.A. Mechanisms of dopamine D1 receptor-mediated ERK1/2 activation in the parkinsonian striatum and their modulation by metabotropic glutamate receptor type 5. J.Neurosci. 2014, 34:4728-4740.
12. Fischer K.D., Houston A.C., Rebec G.V. Role of the major glutamate transporter GLT1 in nucleus accumbens core versus shell in cue-induced cocaine-seeking behavior. J.Neurosci. 2013, 33:9319-9327.
13. Franklin K.B.J., Paxinos G. The Mouse Brain in Stereotaxic Coordinates 2001, Academic Press, San Diego, CA. second ed.
14. Gianforcaro A., Hamadeh M.J. Vitamin D as a potential therapy in amyotrophic lateral sclerosis. CNS Neurosci. Ther. 2014, 20:101-111.
15. Gill S.S., Patel N.K., Hotton G.R., O'Sullivan K., McCarter R., Bunnage M., Brooks D.J., Svendsen C.N., Heywood P. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat. Med. 2003, 9:589-595.
16. Gordon P.H. Amyotrophic lateral sclerosis: an update for 2013 clinical features, pathophysiology, management and therapeutic trials. Aging Dis. 2013, 4:295-310.
17. Hascup K.N., Hascup E.R., Pomerleau F., Huettl P., Gerhardt G.A. Second-by-second measures of L-glutamate in the prefrontal cortex and striatum of freely moving mice. J.Pharmacol. Exp. Ther. 2008, 324:725-731.
18. Ho A., Gore A.C., Weickert C.S., Blum M. Glutamate regulation of GDNF gene expression in the striatum and primary striatal astrocytes. Neuroreport 1995, 6:1454-1458.
19. Hoffman A.F., Gerhardt G.A. Invivo electrochemical studies of dopamine clearance in the rat substantia nigra: effects of locally applied uptake inhibitors and unilateral 6-hydroxydopamine lesions. J.Neurochem. 1998, 70:179-189.
20. Ingram D.K. Age-related decline in physical activity: generalization to nonhumans. Med. Sci. Sports Exerc. 2000, 32:1623-1629.
21. Iribe Y., Moore K., Pang K.C., Tepper J.M. Subthalamic stimulation-induced synaptic responses in substantia nigra pars compacta dopaminergic neurons invitro. J.Neurophysiol. 1999, 82:925-933.
22. Jankovic J. Parkinson's disease: clinical features and diagnosis. J.Neurol. Neurosurg. Psychiatry 2008, 79:368-376.
23. Jenner P., Olanow C.W. Understanding cell death in Parkinson's disease. Ann. Neurol. 1998, 44(3 Suppl 1):S72-S84.
24. Joseph J.A., Fisher D.R., Strain J. Muscarinic receptor subtype determines vulnerability to oxidative stress in COS-7 cells. Free Radic. Biol. Med. 2002, 32:153-161.
25. Kosuge Y., Sekikawa-Nishida K., Negi H., Ishige K., Ito Y. Characterization of chronic glutamate-mediated motor neuron toxicity in organotypic spinal cord culture prepared from ALS model mice. Neurosci. Lett. 2009, 454:165-169.
26. Kruman I.I., Mattson M.P. Pivotal role of mitochondrial calcium uptake in neural cell apoptosis and necrosis. J.Neurochem. 1999, 72:529-540.
27. Lim G.P., Yang F., Chu T., Chen P., Beech W., Teter B., Tran T., Ubeda O., Ashe K.H., Frautschy S.A., Cole G.M. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J.Neurosci. 2000, 20:5709-5714.
28. Lin L.F., Doherty D.H., Lile J.D., Bektesh S., Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 1993, 260:1130-1132.
29. Littrell O.M., Granholm A.C., Gerhardt G.A., Boger H.A. Glial cell-line derived neurotrophic factor (GDNF) replacement attenuates motor impairments and nigrostriatal dopamine deficits in 12-month-old mice with a partial deletion of GDNF. Pharmacol. Biochem. Behav. 2013, 104:10-19.
30. Manev H., Favaron M., Guidotti A., Costa E. Delayed increase of Ca2+ influx elicited by glutamate: role in neuronal death. Mol. Pharmacol. 1989, 36:106-112.
31. Mark K.A., Soghomonian J.J., Yamamoto B.K. High-dose methamphetamine acutely activates the striatonigral pathway to increase striatal glutamate and mediate long-term dopamine toxicity. J.Neurosci. 2004, 24:11449-11456.
32. McGrath J., Lintz E., Hoffer B.J., Gerhardt G.A., Quintero E.M., Granholm A.C. Adeno-associated viral delivery of GDNF promotes recovery of dopaminergic phenotype following a unilateral 6-hydroxydopamine lesion. Cell Transpl. 2002, 11:215-227.
33. Misonou Y., Asahi M., Yokoe S., Miyoshi E., Taniguchi N. Acrolein produces nitric oxide through the elevation of intracellular calcium levels to induce apoptosis in human umbilical vein endothelial cells: implications for smoke angiopathy. Nitric Oxide 2006, 14:180-187.
34. Morris J.K., Bomhoff G.L., Gorres B.K., Davis V.A., Kim J., Lee P.P., Brooks W.M., Gerhardt G.A., Geiger P.C., Stanford J.A. Insulin resistance impairs nigrostriatal dopamine function. Exp. Neurol. 2011, 231:171-180.
35. Pichel J.G., Shen L., Sheng H.Z., Granholm A.C., Drago J., Grinberg A., Lee E.J., Huang S.P., Saarma M., Hoffer B.J., Sariola H., Westphal H. Defects in enteric innervation and kidney development in mice lacking GDNF. Nature 1996, 382:73-76.
36. Quintero J.E., Pomerleau F., Huettl P., Johnson K.W., Offord J., Gerhardt G.A. Methodology for rapid measures of glutamate release in rat brain slices using ceramic-based microelectrode arrays: basic characterization and drug pharmacology. Brain Res. 2011, 1401:1-9.
37. Russo R., Cavaliere F., Varano G.P., Milanese M., Adornetto A., Nucci C., Bonanno G., Morrone L.A., Corasaniti M.T., Bagetta G. Impairment of neuronal glutamate uptake and modulation of the glutamate transporter GLT-1 induced by retinal ischemia. PLoS One 2013, 8:e69250.
38. Slevin J.T., Gerhardt G.A., Smith C.D., Gash D.M., Kryscio R., Young B. Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J.Neurosurg. 2005, 102:216-222.
39. Smith P.J.S., Sanger R.H., Messerli M.A. Principles, development and applications of self-referencing electrochemical microelectrodes to the determination of fluxes at cell membranes. Electrochemical Methods for Neuroscience 2007, CRC Press, Boca Raton, FL. A.C. Michael, L.M. Borland (Eds.).
40. Sofroniew M.V. Molecular dissection of reactive astrogliosis and glial scar formation. Trends Neurosci. 2009, 32:638-647.
41. Sonsalla P.K., Giovanni A., Sieber B.A., Donne K.D., Manzino L. Characteristics of dopaminergic neurotoxicity produced by MPTP and methamphetamine. Ann. N. Y Acad. Sci. 1992, 648:229-238.
42. Varoqui H., Schäfer M.K., Zhu H., Weihe E., Erickson J.D. Identification of the differentiation-associated Na+/PI transporter as a novel vesicular glutamate transporter expressed in a distinct set of glutamatergic synapses. J.Neurosci. 2002, 22:142-155.
43. Volkow N.D., Gur R.C., Wang G.J., Fowler J.S., Moberg P.J., Ding Y.S., Hitzemann R., Smith G., Logan J. Association between decline in brain dopamine activity with age and cognitive and motor impairment in healthy individuals. Am. J. Psychiatry 1998, 155:344-349.